Daclatasvir for the treatment of chronic hepatitis C

@article{Degasperi2015DaclatasvirFT,
  title={Daclatasvir for the treatment of chronic hepatitis C},
  author={Elisabetta Degasperi and Alessio Aghemo and Massimo Colombo},
  journal={Expert Opinion on Pharmacotherapy},
  year={2015},
  volume={16},
  pages={2679 - 2688}
}
  • Elisabetta Degasperi, Alessio Aghemo, Massimo Colombo
  • Published 2015
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • Introduction: Following more than 20 years of Interferon (IFN)-based treatment for hepatitis C virus (HCV), the understanding of viral life cycle led to the development of new antiviral drugs directly targeting HCV replication steps. Daclatasvir (DCV) is a potent inhibitor of non-structural NS5A HCV protein with pangenotypic activity and low-moderate barrier to resistance suitable for IFN-free combination with other direct acting antivirals (DAAs). Areas covered: The present review summarizes… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 66 REFERENCES